These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1342025)

  • 1. Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland.
    Sandyk R
    Int J Neurosci; 1992 Mar; 63(1-2):137-40. PubMed ID: 1342025
    [No Abstract]   [Full Text] [Related]  

  • 2. Magnetic fields in the treatment of Parkinson's disease.
    Sandyk R; Anninos PA; Tsagas N; Derpapas K
    Int J Neurosci; 1992 Mar; 63(1-2):141-50. PubMed ID: 1342026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease.
    Fraix V; Pollak P; Van Blercom N; Xie J; Krack P; Koudsie A; Benabid AL
    Neurology; 2000 Dec; 55(12):1921-3. PubMed ID: 11134399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.
    Russmann H; Ghika J; Combrement P; Villemure JG; Bogousslavsky J; Burkhard PR; Vingerhoets FJ
    Neurology; 2004 Jul; 63(1):153-5. PubMed ID: 15249627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological therapy of complicated Parkinson's disease].
    Jiménez-Jiménez FJ; Molina JA
    Rev Neurol; 1997 Aug; 25 Suppl 2():S170-9. PubMed ID: 9280685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pineal melatonin functions: possible relevance to Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1990 Jan; 50(1-2):37-53. PubMed ID: 2269599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Hz repetitive transcranial magnetic stimulation and diphasic dyskinesia in Parkinson's disease.
    Filipović SR; Bhatia KP; Rothwell JC
    Mov Disord; 2013 Feb; 28(2):245-6. PubMed ID: 23144006
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa therapy in Parkinson's disease.
    Koller WC; Hubble JP
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract]   [Full Text] [Related]  

  • 10. Pineal melatonin and sensory symptoms in Parkinson disease.
    Sandyk R
    Ital J Neurol Sci; 1989 Aug; 10(4):399-403. PubMed ID: 2676905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating Parkinson's disease.
    Standaert D
    Health News; 1998 Nov; 4(14):1-2. PubMed ID: 9825707
    [No Abstract]   [Full Text] [Related]  

  • 12. Pineal melatonin functions and the depression of Parkinson's disease: a hypothesis.
    Sandyk R
    Int J Neurosci; 1990 Mar; 51(1-2):73-7. PubMed ID: 2265910
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications.
    Sandyk R
    Int J Neurosci; 1994; 74(1-4):191-201. PubMed ID: 7928105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of ECT in Parkinson's disease: possible role of pineal melatonin.
    Sandyk R
    Int J Neurosci; 1990 Jan; 50(1-2):83-94. PubMed ID: 2269603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blink reflex in Parkinson's disease with levodopa-induced dyskinesia.
    Iriarte LM; Chacon J; Madrazo J; Chaparro P
    Funct Neurol; 1989; 4(3):257-61. PubMed ID: 2792861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
    Sage JI; Mark MH
    Neurology; 1992 Jan; 42(1 Suppl 1):23-8; discussion 57-60. PubMed ID: 1347908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's disease.
    Obeso JA; Linazasoro G; Guridi J; Ramos E; Rodriguez-Oroz MC
    J Neurol Neurosurg Psychiatry; 2000 Jan; 68(1):122-3. PubMed ID: 10671136
    [No Abstract]   [Full Text] [Related]  

  • 20. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.